Ningling Wang

Partner

Ningling Wang's practice involves patent prosecution, opinions, due diligence, client counseling, licensing, and patent litigation in the areas of chemicals, chemical engineering, pharmaceuticals, medical devices, semiconductor materials, and nanotechnology. She has extensive experience working with multinational and Chinese companies, providing legal advice on IP portfolio management and due diligence. Ms. Wang has been involved in various cases before the U.S. International Trade Commission (ITC) and U.S. district courts.

Ms. Wang speaks frequently in conferences and seminars in China and internationally on patent-related topics. She taught a graduate course on U.S. IP law at Renmin University of China Law School and a graduate course on U.S. IP law, with patent mock trial, at Shanghai Jiao Tong University KoGuan Law School. She also serves as a program professor of Law at China Science and Technology University.

Highlights

• Represented five Chinese LED companies in defense of ITC litigations.
• Conducted due diligence for multinational and Chinese companies.
• Represented multinational and Chinese companies in IP portfolio management.
• Represented a large U.S. pharmaceutical company in an Abbreviated New Drug Application (ANDA) litigation.
• Law clerk to the Honorable Ann Aiken of the U.S. District Court for the District of Oregon, 2000.
• Managing editor of the Oregon Law Review, 2000-2001.
• Worked at Liu, Shen & Associates in Beijing, China, 1994-1995; and Genentech, 1998.

Professional Recognition

• Order of the Coif.

Professional Activities

• Licensing Executives Society International (vice-chair, Asia Pacific Committee, 2011)
• American Chamber of Commerce, Shanghai (co-chair, IP Committee, 2010-present)
• Licensing Executives Society, China (Board of Directors, 2009-present)
• BayHelix Group
• Federal Circuit Bar Association
• American Intellectual Property Law Association
• American Bar Association

Select Publications

• "Impacts of America Invents Act on Chinese Import and Export Companies," Imp-Exp Executive, Nov. 2011.
• Coauthor. "2010 USPTO Guidelines for Examination of Obviousness," MIP Chinese Edition, June 2011.
• Coauthor. "Ariad v. Lilly: Written Description Requirement Separate from Enablement Requirement," China IP News, July 14, 2010.
• Coauthor. "What Could Chinese Companies Learn from i4i v. Microsoft Case?" LexisNexis China Legal Review, June 2010.
• Coauthor. "Intellectual Property Due Diligence in View of Global Innovation," China Intellectual Property, April 2010. 
• Coauthor. "Managing U.S. Patent Litigation Risks Caused by Export Activities," Imp-Exp Executives, Nov. 2009.
• Coauthor. "Obviousness Developments in U.S. Patent Law," China IP News, July 9, 2009. (Ranked by Mondaq as its most popular article in the United States in January 2010).
• Coauthor. "Practical Considerations and Strategies in Drafting U.S. Patent Applications," China IP News, April 10, 2009.
• Coauthor. "Most Recent Trend and Defense Strategies in Rule 337 Investigations at U.S. ITC.," China IP News, April 2008.
• Coauthor. "Build Assets Today for Business Tomorrow," Managing Intellectual Property: China IP Focus 2008, March 2008.